pruritus associated with chronic kidney disease
Rare disease · 2023–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| difelikefalin Treatment of moderate to severe pruritus associated with chronic kidney disease in adult patients on haemodialysis. | Mar 2023 | Not recommended | input received Kidney Health Australia · Renal Society of Australia |
| difelikefalin Treatment of moderate to severe pruritus associated with chronic kidney disease in adult patients on haemodialysis who have inadequate response to best… | Nov 2023 | Recommended with restriction | 4 individuals Kidney Health Australia |
Who spoke
Kidney Health Australia · Renal Society of Australia
What the PBS pays
$1M in government benefit over 2024–25, across 2,481 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| difelikefalin | $1.4M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.